Unlocking the Potential: FibroGen’s Groundbreaking Findings from the Phase 3 Matterhorn Trial of Roxadustat at the American Society of Hematology Annual Meeting
FibroGen Presents Data from Phase 3 MATTERHORN Trial of Roxadustat A Groundbreaking Study in Anemia Treatment A recent post hoc analysis of data from the Phase 3 MATTERHORN trial has revealed exciting results for patients with anemia of lower risk transfusion-dependent. The study focused on the efficacy of roxadustat compared to a placebo in achieving…